IDEXX Laboratories Inc

IDEXX Laboratories Inc(IDXX)の株式分析

$545.160

-11.285 (-2.07%)終値時点

Loading chart…
High
555.950
Open
555.950
VWAP
547.55
Vol
458.29K
Mkt Cap
40.79B
Low
541.530
Amount
250.93M
EV/EBITDA, TTM
24.75

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants.

www.idexx.com

AI analysis of IDEXX Laboratories Inc (IDXX)

hold

IDEXX Laboratories is currently a hold. The stock is priced at $554.99, which is below the lowest analyst target of $620 from UBS, indicating potential for upside. However, the RSI is at 49.226, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 37.45, which is relatively high, indicating that the stock may be overvalued at this price point. The main risk is the recent downgrade from Barclays, which lowered its price target from $800 to $710, reflecting cautious sentiment in the market.

Analyst Ratings (10)

+45.42% upside
Buy
6 Buy
3 Hold
1 Sell
Current: 545.16
安値
750.00
平均
792.78
高値
850.00

Barclays

2026-08-11

目標株価

$710

Overweight

Citi

2026-08-05

目標株価

$670

Neutral

UBS

2026-07-27

目標株価

$620

Neutral

Stifel

2026-07-15

目標株価

$564.42

Buy

BofA

2026-05-05

目標株価

$660

Neutral

バリュエーション指標

The current forward P/E ratio for IDEXX Laboratories Inc (IDXX) is 36.90, compared to its 5-year average forward P/E of 47.04.

Forward P/E

Undervalued
5Y Average P/E
47.04
Current P/E
36.90
割高
57.05
割安
37.03

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
32.75
Current EV/EBITDA
24.75
割高
39.45
割安
26.05

Forward P/S

Fair
5Y Average P/S
10.52
Current P/S
8.53
割高
12.54
割安
8.50

Alphio AI Price Scenarios for IDXX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IDXX

$650.45

シナリオ価格

B

Base

Base · 50%IDXX

$608.98

シナリオ価格

B

Bear

Bear · 25%IDXX

$597.63

シナリオ価格

Whales holding IDXX

B

Bellevue Asset Management AG

+ HoldingIDXX

+9.89%

3M Return

C

Chilton Investment Company, Inc.

+ HoldingIDXX

+7.34%

3M Return

T

Tremblant Capital Group

+ HoldingIDXX

+6.35%

3M Return

V

Veritas Investment Management LLP

+ HoldingIDXX

+4.53%

3M Return

B

Bradley, Foster & Sargent, Inc.

+ HoldingIDXX

+4.33%

3M Return

F

Fundsmith, LLP

+ HoldingIDXX

+3.15%

3M Return

イベントタイムライン

2026-08-11 (ET)

07:30:00

IDEXX Launches Catalyst proBNP Test, Enhancing Cardiac Testing Capabilities

2026-08-04 (ET)

09:00:00

IDEXX Laboratories Q2 Revenue $1.22B Beats Expectations

08:30:00

Idexx Reports Q2 EPS of $4.27, Beating Consensus of $3.93

07:00:00

2026 EPS Consensus at $14.66, Revenue View Adjusted to $4.70B-$4.745B

07:00:00

IDEXX Laboratories Reports Q2 Revenue of $1.22B

ニュース

IDXX FAQ — answered by Alphio AI

IDEXX Laboratories, Inc. develops, manufactures, and distributes products and provides services primarily for the companion animal veterinary; livestock, poultry and dairy; and water testing industries. It also manufactures and sells human medical point-of-care diagnostic products. Its products and services include point-of-care veterinary diagnostic products, comprised of instruments, consumables, and rapid assay test kits. It also includes veterinary reference laboratory diagnostic and consulting services. It offers practice management systems, software and diagnostic imaging systems and services used by veterinarians. It also offers health monitoring, biological materials testing, laboratory diagnostic instruments, and services used by the biomedical research community. The Company provides diagnostic and health-monitoring products for livestock, poultry, and dairy; and products that test water for certain microbiological contaminants. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

IDEXX Laboratories is currently a hold. The stock is priced at $554.99, which is below the lowest analyst target of $620 from UBS, indicating potential for upside. However, the RSI is at 49.226, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 37.45, which is relatively high, indicating that the stock may be overvalued at this price point. The main risk is the recent downgrade from Barclays, which lowered its price target from $800 to $710, reflecting cautious sentiment in the market.

10 analysts cover IDXX: 6 rate it Buy, 3 Hold and 1 Sell. The average price target is 792.78.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める